Evaluation of the WMS-III Rarely Missed Index in a naive clinical sample.

We examined the WMS-III Rarely Missed Index as a reliable predictor of fabrication of memory difficulties. A total of 31 outpatients referred for neuropsychological evaluation completed the WMS-III Logical Memory Delayed Recognition Test (LMDR) before having heard the stories and again after hearing the stories. Of the 30 items from the LMDR completed by participants who had not heard the stories, 5 were found to significantly differ from chance; only 1 of those items was found to do so in the original RMI studies.

Pilot trial of memantine in the treatment of posttraumatic stress disorder.

This multiple case series was initially designed as a prospective, open-label, 12-week trial investigation evaluating memantine (Namenda) for the treatment of psychiatric and cognitive symptoms associated with PTSD. In a selected, small sample of individuals (n = 4) with combat PTSD, treatment with memantine produced consistent improvement on a delayed recall measure of memory, variable reduction of depressive symptoms, and variable reduction in hyperarousal symptoms. These data suggest potential positive treatment outcomes, both cognitively and psychiatrically, and provide rationale for future double-blind, placebo-controlled studies of memantine in PTSD.